Analysis of prospective propranolol clinical trials data for correlations between progression free survival, overall survival and changes in the biomarkers of ADRB2/PKA activity, apoptosis and angiogenesis will inform whether biomarkers discussed in this review can segregate prostate cancer patients into propranolol responsive and nonresponsive groups. This evidence concerns the gene ADRB2 and prostate carcinoma.